OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation Corneal
Conditions
Inflammation Corneal, Pain, Postoperative
Trial Timeline
Sep 27, 2019 → Jan 31, 2020
NCT ID
NCT04130802About OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo is a phase 2 stage product being developed by Oculis Holding AG for Inflammation Corneal. The current trial status is completed. This product is registered under clinical trial identifier NCT04130802. Target conditions include Inflammation Corneal, Pain, Postoperative.
What happened to similar drugs?
2 of 15 similar drugs in Inflammation Corneal were approved
Approved (2) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04130802 | Phase 2 | Completed |
Competing Products
20 competing products in Inflammation Corneal